Detailed entry information

Protein Information (annotations from UniProt)

Database IDHIV0006491
UniProt IDP17612
Primary gene name(s)PRKACA
Synonym gene name(s)PKACA
Protein namecAMP-dependent protein kinase catalytic subunit alpha
Protein functionPhosphorylates a large number of substrates in the cytoplasm and the nucleus. Regulates the abundance of compartmentalized pools of its regulatory subunits through phosphorylation of PJA2 which binds and ubiquitinates these subunits, leading to their subsequent proteolysis. Phosphorylates CDC25B, ABL1, NFKB1, CLDN3, PSMC5/RPT6, PJA2, RYR2, RORA and VASP. RORA is activated by phosphorylation. Required for glucose-mediated adipogenic differentiation increase and osteogenic differentiation inhibition from osteoblasts. Involved in the regulation of platelets in response to thrombin and collagen; maintains circulating platelets in a resting state by phosphorylating proteins in numerous platelet inhibitory pathways when in complex with NF-kappa-B, NFKB1 and NFKB2 and I-kappa-B-alpha, NFKBIA, but thrombin and collagen disrupt these complexes and free active PRKACA stimulates platelets and leads to platelet aggregation by phosphorylating VASP. Prevents the antiproliferative and anti-invasive effects of alpha-difluoromethylornithine in breast cancer cells when activated. RYR2 channel activity is potentiated by phosphorylation in presence of luminal Ca(2+, leading to reduced amplitude and increased frequency of store overload-induced Ca(2+ release, SOICR characterized by an increased rate of Ca(2+ release and propagation velocity of spontaneous Ca(2+ waves, despite reduced wave amplitude and resting cytosolic Ca(2+. PSMC5/RPT6 activation by phosphorylation stimulates proteasome. Negatively regulates tight junctions, TJs in ovarian cancer cells via CLDN3 phosphorylation. NFKB1 phosphorylation promotes NF-kappa-B p50-p50 DNA binding. Involved in embryonic development by down-regulating the Hedgehog, Hh signaling pathway that determines embryo pattern formation and morphogenesis. Prevents meiosis resumption in prophase-arrested oocytes via CDC25B inactivation by phosphorylation. May also regulate rapid eye movement, REM sleep in the pedunculopontine tegmental, PPT. Phosphorylates APOBEC3G and AICDA. Isoform 2 phosphorylates and activates ABL1 in sperm flagellum to promote spermatozoa capacitation. {ECO:0000269|PubMed:15642694, ECO:0000269|PubMed:15905176, ECO:0000269|PubMed:16387847, ECO:0000269|PubMed:17333334, ECO:0000269|PubMed:17565987, ECO:0000269|PubMed:17693412, ECO:0000269|PubMed:18836454, ECO:0000269|PubMed:19949837, ECO:0000269|PubMed:20356841, ECO:0000269|PubMed:21423175, ECO:0000269|PubMed:21514275, ECO:0000269|PubMed:21812984}.
Subcellular locationCytoplasm. Cell membrane. Nucleus {ECO:0000250}. Mitochondrion {ECO:0000250}. Membrane {ECO:0000305};
Lipid-anchor {ECO:0000305}. Note=Translocates into the nucleus, monomeric catalytic subunit. The inactive holoenzyme is found in the cytoplasm. Distributed throughout the cytoplasm in meiotically incompetent oocytes. Associated to mitochondrion as meiotic competence is acquired. Aggregates around the germinal vesicles, GV at the immature GV stage oocytes, By similarity. {ECO:0000250}.;
SUBCELLULAR LOCATION: Isoform 2: Cell projection, cilium, flagellum {ECO:0000269|PubMed:10906071}. Cytoplasmic vesicle, secretory vesicle, acrosome {ECO:0000250|UniProtKB:P05132}. Note=Expressed in the midpiece region of the sperm flagellum, PubMed:10906071. Colocalizes with MROH2B and TCP11 on the acrosome and tail regions in round spermatids and spermatozoa regardless of the capacitation status of the sperm, By similarity. {ECO:0000250|UniProtKB:P05132, ECO:0000269|PubMed:10906071}.
ECO codeClick here for more information.
Amino acid sequence
FASTA format: P17612
Gene Ontology
(Biological Process)
Complete annatation
activation of protein kinase A activity [GO:0034199];
blood coagulation [GO:0007596];
calcium-mediated signaling using intracellular calcium source [GO:0035584];
cell communication by electrical coupling involved in cardiac conduction [GO:0086064];
cellular response to epinephrine stimulus [GO:0071872];
cellular response to glucagon stimulus [GO:0071377];
cellular response to glucose stimulus [GO:0071333];
cellular response to parathyroid hormone stimulus [GO:0071374];
G2/M transition of mitotic cell cycle [GO:0000086];
lipoprotein metabolic process [GO:0042157];
mesoderm formation [GO:0001707];
modulation of synaptic transmission [GO:0050804];
mRNA processing [GO:0006397];
negative regulation of smoothened signaling pathway involved in dorsal/ventral neural tube patterning [GO:1901621];
neural tube closure [GO:0001843];
peptidyl-serine phosphorylation [GO:0018105];
peptidyl-threonine phosphorylation [GO:0018107];
positive regulation of cell cycle arrest [GO:0071158];
positive regulation of protein export from nucleus [GO:0046827];
protein autophosphorylation [GO:0046777];
protein phosphorylation [GO:0006468];
regulation of bicellular tight junction assembly [GO:2000810];
regulation of cardiac conduction [GO:1903779];
regulation of cardiac muscle contraction [GO:0055117];
regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ion [GO:0010881];
regulation of cytosolic calcium ion concentration [GO:0051480];
regulation of heart rate [GO:0002027];
regulation of osteoblast differentiation [GO:0045667];
regulation of proteasomal protein catabolic process [GO:0061136];
regulation of protein binding [GO:0043393];
regulation of protein processing [GO:0070613];
regulation of ryanodine-sensitive calcium-release channel activity [GO:0060314];
renal water homeostasis [GO:0003091];
sperm capacitation [GO:0048240];
stimulatory C-type lectin receptor signaling pathway [GO:0002223]
Gene Ontology
(Molecular Function)
Complete annatation
ATP binding [GO:0005524];
cAMP-dependent protein kinase activity [GO:0004691];
protein kinase A regulatory subunit binding [GO:0034237];
protein kinase binding [GO:0019901];
protein serine/threonine/tyrosine kinase activity [GO:0004712];
protein serine/threonine kinase activity [GO:0004674];
ubiquitin protein ligase binding [GO:0031625]
Gene Ontology
(Cellular Component)
Complete annatation
calcium channel complex [GO:0034704];
cAMP-dependent protein kinase complex [GO:0005952];
centrosome [GO:0005813];
ciliary base [GO:0097546];
cytosol [GO:0005829];
extracellular exosome [GO:0070062];
Golgi apparatus [GO:0005794];
mitochondrion [GO:0005739];
motile cilium [GO:0031514];
neuromuscular junction [GO:0031594];
neuron projection [GO:0043005];
nuclear speck [GO:0016607];
nucleoplasm [GO:0005654];
nucleotide-activated protein kinase complex [GO:0031588];
nucleus [GO:0005634];
perinuclear region of cytoplasm [GO:0048471];
plasma membrane raft [GO:0044853];
sperm midpiece [GO:0097225]
Protein-protein interaction111553
Phylogenetic treeP17612
HIV replication factor status Zhou et al., Cell. Host. Microbe., 2008
Brass et al., Science, 2008
Smith et al., J. Immunol, 2010
gene status
Lu et al., J. Virol., 2011
      Folds changes 8h: unknown; Folds changes 16h: unknown; Tested: unknown;
Schoggins JW and Rice CM, Curr. Opin. Virol., 2011
      Targeted viruses: unknown
      Viral life cycle: unknown
      Mechanism related to antiviral activity: unknown
Anti-viral restriction factor Liu et al., Retrovirology, 2011
      unknown (Triplicates)

Gene Expression Profile       top

            Up-regulated;            Down-regulated

For brief introduction to each study, please go to the help page.

Gene expression during HIV latency

(1). Mohammadi et al., PLoS Pathog., 2014

Differentially expressed transcripts (Pairwise) during latency and subsequent viral reactivation using several agents - Primary CD4+ T-cell based model

DMSO: Dimethyl suloxyde (negative control) - 0.0033% final
SAHA: Vorinostat (Histone deacetylase inhibitor) - 0.5 μM
CD3: TCR Stimulation by IL-2+ antiCD3/anti-CD28 antibodies
IL7: Interleukin-7 based stimulation
DISU: Disulfiram (alcohol dehydrogenase inhibitor) - 0.5 μM
AZA: 5-azacytidine (AZA; DNA methylation inhibitor) - 1 μM
Experimental Condition Log2 Fold Change P value Adjusted P value
AZA vs. CD3-0.3492051568389760.3661719504263880.487798008310824
AZA vs. DISU-0.1054060651237640.6778679384821610.964884761087644
AZA vs. IL70.01011743405006580.9582873365043530.999311006273513
AZA vs. SAHA0.5712062571008930.06498043895738190.312944133176861
DISU vs. CD30.2325781822644680.5606613694932630.678610043659985
DISU vs. IL70.1059212428090970.6747515927235050.911132233993804
DISU vs. SAHA0.6786339611166550.04296380261224350.257038232090635
DMSO vs. AZA-0.07806344008660840.6438103147678351
DMSO vs. CD30.2598244473664110.497926941866680.606604348958558
DMSO vs. DISU0.0254112207070940.917246677389430.988794449860557
DMSO vs. IL70.09560981533382990.5970021488403010.911970258876874
DMSO vs. SAHA0.6438291392329630.03648448880452760.208647949916657
HIV vs. Mock in Activation0.1326666856156370.8786092061452210.999983755607037
HIV vs. Mock in Latency-0.04301195183650080.7958329613747530.999834320637052
IL7 vs. CD30.3655982332345050.3433482879100660.480572824186873
SAHA vs. CD30.8967641951861790.08188640356898580.148249411555096
SAHA vs. IL70.558725803956710.08141730853457550.253571179514502
(2). Iglesias-Ussel et al., J. Virol., 2013

Up and Downregulated transcripts during Latency (Latently infected CD4+ T cells vs Uninfected)- Primary CD4+Tcell based model
Log2 Fold Change P Value
unknown unknown

Gene expression during HIV infection and replication

(1). Imbeault et al., PloS Pathog., 2012

Transcriptomic profiling of HIV-1 infected CD4+ T cells - Primary CD4+ T cells
Experiment type Log2 Fold Change P Value Adjusted P Value
Infected vs. Mock unknown unknown unknown
Infected vs. Bystander unknown unknown unknown
(2). Lefebvre et al., J. Virol., 2011

Transcriptome analysis of T-cell line (Sup T1)
Log2 Fold Change unknown
(3). Li et al., J. Immunol., 2013

Lymphatic tissue
Acute Fold Change Acute P Value Asymt Fold Change Asypt P Value AIDS Fold Change AIDS P Value
unknown unknown unknown unknown unknown unknown
(4). Chang et al., MBio., 2011

Transcriptome analysis of T-cell line (Sup T1)

Derived from Sherrill-Mix et al., BMC Retrovirol., 2015 cross validation
Up-regulated (True) unknown
(5). Sherrill-Mix et al., BMC Retrovirol., 2015

Deep RNA-seq analysis of primary human T cell infected with low passage HIV isolate HIV89.6 - Primary CD4+ T cell based
Test Status Log2 Fold Change P Value
OK -0.260714 0.0727566
(6). Rotger et al., PLoS Pathog., 2010

Genome-wide mRNA expression of CD4+ T cells from HIV-infected patient
(Genes differentially expressed (at adjusted p<0.01) according to the empirical Bayes approach)
Log2 Fold Change P Value
unknown unknown

Proteomic/Transcriptomics studies indicating differentially expressed genes mediated by HIV

(1). Greenwood et al., Elife, 2016

Activated (CD3/CD28) Primary human CD4+ T cells infected with pNL4-3-dE-EGFP. The table shows the complete (unfiltered) TMT (tandem mass tag)-based proteomic time course dataset
6 h 24 h 48 h 72 h RTi
0.998 0.947 1.046 1.096 0.935
(2). Navare et al., Virology, 2012

SUP-T1 cell line
FC-4hpi P-value FC-8hpi P-value FC-20hpi P-value Category
unknown unknown unknown unknown unknown unknown unknown
(3). Hyrcza et al., J. Virolo., 2007

Primary human CD4+ and CD8+ T Cells
Affymetrix Prob ID Fold Change In CD8? Category
unknown unknown unknown unknown

Protein Overview       top

Drug-protein Interaction       (annotations from DrugBank)      top

Drugbank ID Drug Name Drug Status Pharmacological Action Drug Action
DB01919 Pentanal experimental unknown unknown
DB01940 Balanol Analog 2 experimental unknown unknown
DB02155 Balanol Analog 8 experimental unknown unknown
DB04098 Balanol experimental unknown unknown
DB04530 S,S-(2-Hydroxyethyl)Thiocysteine experimental unknown unknown
DB02482 Phosphonothreonine experimental unknown unknown
DB04522 Phosphonoserine experimental unknown unknown
DB06959 (1S)-2-(1H-INDOL-3-YL)-1-{[(5-ISOQUINOLIN-6-YLPYRIDIN-3-YL)OXY]METHYL}ETHYLAMINE experimental unknown unknown
DB06977 (2S)-1-{[5-(1H-INDAZOL-5-YL)PYRIDIN-3-YL]OXY}-3-[(7AS)-7AH-INDOL-3-YL]PROPAN-2-AMINE experimental unknown unknown
DB07107 (1S)-2-(1H-INDOL-3-YL)-1-[({5-[(E)-2-PYRIDIN-4-YLVINYL]PYRIDIN-3-YL}OXY)METHYL]ETHYLAMINE experimental unknown unknown
DB07124 (2S)-1-(6H-INDOL-3-YL)-3-{[5-(7H-PYRAZOLO[3,4-C]PYRIDIN-5-YL)PYRIDIN-3-YL]OXY}PROPAN-2-AMINE experimental unknown unknown
DB07204 (1S)-1-(1H-INDOL-3-YLMETHYL)-2-(2-PYRIDIN-4-YL-[1,7]NAPHTYRIDIN-5-YLOXY)-EHYLAMINE experimental unknown unknown
DB02611 Balanol Analog 1 experimental unknown unknown
DB07458 3-(1H-INDOL-3-YL)-4-{1-[2-(1-METHYLPYRROLIDIN-2-YL)ETHYL]-1H-INDOL-3-YL}-1H-PYRROLE-2,5-DIONE experimental unknown unknown
DB07583 (4R,2S)-5&,39;-(4-(4-CHLOROBENZYLOXY)PYRROLIDIN-2-YLMETHANESULFONYL)ISOQUINOLINE experimental unknown unknown
DB07854 N-METHYL-1-[4-(9H-PURIN-6-YL)PHENYL]METHANAMINE experimental unknown unknown
DB07855 (S)-1-PHENYL-1-[4-(9H-PURIN-6-YL)PHENYL]METHANAMINE experimental unknown unknown
DB07856 6-{4-[4-(4-CHLOROPHENYL)PIPERIDIN-4-YL]PHENYL}-9H-PURINE experimental unknown unknown
DB07857 (2R)-2-(4-CHLOROPHENYL)-2-[4-(1H-PYRAZOL-4-YL)PHENYL]ETHANAMINE experimental unknown unknown
DB07858 (2S)-2-(4-CHLOROPHENYL)-2-[4-(1H-PYRAZOL-4-YL)PHENYL]ETHANAMINE experimental unknown unknown
DB07859 4-(4-CHLOROPHENYL)-4-[4-(1H-PYRAZOL-4-YL)PHENYL]PIPERIDINE experimental unknown unknown
DB07860 (2R)-2-(4-CHLOROPHENYL)-2-PHENYLETHANAMINE experimental unknown unknown
DB07876 (S)-2-METHYL-1-[(4-METHYL-5-ISOQUINOLINE)SULFONYL]-HOMOPIPERAZINE experimental unknown unknown
DB04707 HYDROXYFASUDIL experimental unknown unknown
DB07996 5-(2-methylpiperazine-1-sulfonyl)isoquinoline experimental unknown unknown
DB07997 N-[2-(METHYLAMINO)ETHYL]-5-ISOQUINOLINESULFONAMIDE experimental unknown unknown
DB08070 2-[4-(3-METHYL-1H-PYRAZOL-4-YL)PHENYL]ETHANAMINE experimental unknown unknown
DB08073 (2S)-1-(1H-INDOL-3-YL)-3-{[5-(3-METHYL-1H-INDAZOL-5-YL)PYRIDIN-3-YL]OXY}PROPAN-2-AMINE experimental unknown unknown
DB08113 3-pyridin-4-yl-1H-indazole experimental unknown unknown
DB08114 5-benzyl-1,3-thiazol-2-amine experimental unknown unknown
DB08148 1-[4-(4-chlorophenyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-yl]methanamine experimental unknown unknown
DB08149 1-[4-(4-chlorobenzyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-yl]methanamine experimental unknown unknown
DB08150 4-(4-chlorobenzyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-aminium experimental unknown unknown
DB08162 5-(1,4-DIAZEPAN-1-SULFONYL)ISOQUINOLINE experimental unknown unknown
DB08231 MYRISTIC ACID experimental unknown unknown
DB08568 (2S)-1-{[5-(3-METHYL-1H-INDAZOL-5-YL)PYRIDIN-3-YL]OXY}-3-PHENYLPROPAN-2-AMINE experimental unknown unknown
DB08569 3-PYRIDIN-4-YL-2,4-DIHYDRO-INDENO[1,2-.C.] PYRAZOLE experimental unknown unknown
DB03374 3,5-Diiodotyrosine experimental unknown unknown
DB08756 (R)-TRANS-4-(1-AMINOETHYL)-N-(4-PYRIDYL) CYCLOHEXANECARBOXAMIDE experimental unknown unknown
DB08846 Ellagic Acid investigational unknown inhibitor, competitive

Protein Secondary Structure       (annotations from PDB)      top

PDB Accession Method Resolution Chain Structure Preview
2GU8 X-ray 2.2Å A=15-351.
3AGL X-ray 2.1Å A/B=1-351.
3AGM X-ray 2.0Å A=1-351.
3AMA X-ray 1.7Å A=1-351.
3AMB X-ray 2.2Å A=1-351.
3L9L X-ray 2.0Å A/B=1-351.
3L9M X-ray 1.9Å A/B=1-351.
3L9N X-ray 2.0Å A=1-351.
3MVJ X-ray 2.4Å A/B/E=1-351.
3NX8 X-ray 2.0Å A=1-351.
3OOG X-ray 2.0Å A=1-351.
3OVV X-ray 1.5Å A=1-351.
3OWP X-ray 1.8Å A=1-351.
3OXT X-ray 2.2Å A=1-351.
3P0M X-ray 2.0Å A=1-351.
3POO X-ray 1.6Å A=1-351.
3VQH X-ray 1.9Å A=1-351.
4AE6 X-ray 2.1Å A/B=16-351.
4AE9 X-ray 2.3Å A/B=16-351.
4UJ1 X-ray 1.7Å A=1-351.
4UJ2 X-ray 2.0Å A=1-351.
4UJ9 X-ray 1.8Å A=1-351.
4UJA X-ray 1.9Å A=1-351.
4UJB X-ray 1.9Å A=1-351.
4WB5 X-ray 1.6Å A=2-351.
4WB6 X-ray 2.1Å A/B=2-351.
4WB7 X-ray 1.9Å A/B=16-351.
4WB8 X-ray 1.5Å A=16-351.
5BX6 X-ray 1.8Å A=1-351.
5BX7 X-ray 1.8Å A=1-350.
5IZF X-ray 2.1Å A=1-351.
5IZJ X-ray 1.8Å A/B=1-351.
5J5X X-ray 2.6Å A=1-351.

HIV-1 Interaction       (annotations from NCBI HIV-1 Interaction Database)      top

HIV Partner Interaction Type PubMed
Envelope surface glycoprotein gp120 interacts with 12972513
Nef phosphorylated by 15629779
Tat activates 9278385
Vif inhibited by 18836454
Tat upregulates 21745501
Vpr phosphorylated by 20392842
Vpr interacts with 24282540
matrix phosphorylated by 9151826
Tat inhibits 20433920
Envelope surface glycoprotein gp120 inhibited by 19100722
capsid phosphorylated by 12842892
Envelope surface glycoprotein gp120 inactivates 9540970
matrix activates 1978848

Metabolic/Signalling Pathway       (annotations from KEGG database)      top

Pathway Accession Number Description
hsa01522 Endocrine resistance - Homo sapiens (human)
hsa04010 MAPK signaling pathway - Homo sapiens (human)
hsa04014 Ras signaling pathway - Homo sapiens (human)
hsa04020 Calcium signaling pathway - Homo sapiens (human)
hsa04024 cAMP signaling pathway - Homo sapiens (human)
hsa04062 Chemokine signaling pathway - Homo sapiens (human)
hsa04114 Oocyte meiosis - Homo sapiens (human)
hsa04211 Longevity regulating pathway - Homo sapiens (human)
hsa04213 Longevity regulating pathway - multiple species - Homo sapiens (human)
hsa04261 Adrenergic signaling in cardiomyocytes - Homo sapiens (human)
hsa04270 Vascular smooth muscle contraction - Homo sapiens (human)
hsa04310 Wnt signaling pathway - Homo sapiens (human)
hsa04340 Hedgehog signaling pathway - Homo sapiens (human)
hsa04530 Tight junction - Homo sapiens (human)
hsa04540 Gap junction - Homo sapiens (human)
hsa04611 Platelet activation - Homo sapiens (human)
hsa04713 Circadian entrainment - Homo sapiens (human)
hsa04720 Long-term potentiation - Homo sapiens (human)
hsa04723 Retrograde endocannabinoid signaling - Homo sapiens (human)
hsa04724 Glutamatergic synapse - Homo sapiens (human)
hsa04725 Cholinergic synapse - Homo sapiens (human)
hsa04726 Serotonergic synapse - Homo sapiens (human)
hsa04727 GABAergic synapse - Homo sapiens (human)
hsa04728 Dopaminergic synapse - Homo sapiens (human)
hsa04740 Olfactory transduction - Homo sapiens (human)
hsa04742 Taste transduction - Homo sapiens (human)
hsa04750 Inflammatory mediator regulation of TRP channels - Homo sapiens (human)
hsa04910 Insulin signaling pathway - Homo sapiens (human)
hsa04911 Insulin secretion - Homo sapiens (human)
hsa04912 GnRH signaling pathway - Homo sapiens (human)
hsa04913 Ovarian steroidogenesis - Homo sapiens (human)
hsa04914 Progesterone-mediated oocyte maturation - Homo sapiens (human)
hsa04915 Estrogen signaling pathway - Homo sapiens (human)
hsa04916 Melanogenesis - Homo sapiens (human)
hsa04918 Thyroid hormone synthesis - Homo sapiens (human)
hsa04919 Thyroid hormone signaling pathway - Homo sapiens (human)
hsa04921 Oxytocin signaling pathway - Homo sapiens (human)
hsa04922 Glucagon signaling pathway - Homo sapiens (human)
hsa04923 Regulation of lipolysis in adipocytes - Homo sapiens (human)
hsa04924 Renin secretion - Homo sapiens (human)
hsa04925 Aldosterone synthesis and secretion - Homo sapiens (human)
hsa04961 Endocrine and other factor-regulated calcium reabsorption - Homo sapiens (human)
hsa04962 Vasopressin-regulated water reabsorption - Homo sapiens (human)
hsa04970 Salivary secretion - Homo sapiens (human)
hsa04971 Gastric acid secretion - Homo sapiens (human)
hsa04976 Bile secretion - Homo sapiens (human)
hsa05012 Parkinson's disease - Homo sapiens (human)
hsa05020 Prion diseases - Homo sapiens (human)
hsa05030 Cocaine addiction - Homo sapiens (human)
hsa05031 Amphetamine addiction - Homo sapiens (human)
hsa05032 Morphine addiction - Homo sapiens (human)
hsa05034 Alcoholism - Homo sapiens (human)
hsa05110 Vibrio cholerae infection - Homo sapiens (human)
hsa05146 Amoebiasis - Homo sapiens (human)
hsa05166 HTLV-I infection - Homo sapiens (human)
hsa05169 Epstein-Barr virus infection - Homo sapiens (human)
hsa05200 Pathways in cancer - Homo sapiens (human)
hsa05203 Viral carcinogenesis - Homo sapiens (human)
hsa05205 Proteoglycans in cancer - Homo sapiens (human)
hsa05414 Dilated cardiomyopathy - Homo sapiens (human)